Khurshid Guru, MD, Director of the Center for Robotic Surgery at Roswell Park Cancer Institute (RPCI) has been named the institute's second Dr. Robert P. Huben Professor of Urologic Oncology, a professorship established in 2006 to support urologic education and research.
Guru and his Roswell Park team pioneered RPCI's program for robotic cystectomy; he performed the first robot-assisted cystectomy in Western New York in November 2005, and performs live demonstrations of robot-assisted prostatectomy at international seminars.
In 2010, he and his collaborators at the University at Buffalo's School of Engineering and Applied Sciences introduced the first robot-assisted surgical simulator that mimics the daVinci robotic surgical system, and last year his company, Simulated Surgical Systems LLC, a spinoff company of RPCI, launched the first procedure-specific software modules for robot-assisted surgery.
Frederick F. Becker, MD, Professor of Molecular Pathology at the University of Texas MD Anderson Cancer Center, will receive the 2012 American Society for Investigative Pathology Gold-Headed Cane Award later this month, in recognition of his research, teaching, and leadership in academic medicine. His research has focused on epigenetic changes during pre-malignancy and in malignant tumors. He has developed a biophysical technology capable of identifying the electronic phenotype of individual cells, which could have application in separating malignant cells from blood and cell mixtures for subsequent analysis.
Albert B. Einstein, Jr., MD, has been awarded the Association of Community Cancer Center's David King Community Clinical Scientist Award for outstanding service, leadership, and commitment to the oncology community. He is recognized for his work in cancer program development and chemotherapy for genitourinary cancers, according to a statement.
He practiced medical oncology for 17 years at Virginia Mason Clinic in Seattle, where he was a member of the Executive Committee of the National Bladder Cancer Collaborative Group A, founder and principal investigator of the Virginia Mason Community Clinical Oncology Program, Chairperson for bladder cancer research for the Southwest Oncology Group Genitourinary Committee, President of the Virginia Mason Research Center, and Medical Director of the Virginia Mason cancer program.
In 1993 he returned to academic medicine at H. Lee Moffitt Cancer Center and Research Center, during which time he helped to develop the center into a NCI-designated cancer center, and in 1999 he returned to Seattle to establish and direct the Swedish Cancer Institute at the Swedish Medical Center, the largest comprehensive cancer program in the State of Washington.
Michael Maitland, MD, PhD, Assistant Director for Clinician Education in the Center for Personalized Therapeutics and Assistant Professor of Medicine at the University of Chicago, received the Leon I. Goldberg Young Investigator Award from the American Society for Clinical Pharmacology and Therapeutics.
The Oncology Nursing Society has selected Moffitt Cancer Center to receive the 2012 Employer Recognition Award for large employers to recognize employers who show exemplary support of their registered oncology nurses. Moffitt recognizes its oncology nurses by rewarding those who become certified; offering two scholarships per year for nurses to attend the national ONS conference of their choice; granting three paid professional development days each year for nurses to attend professional conferences; and purchasing, using and disseminating ONS materials such as standards, guidelines, and other resources to their nurses.
“In 2011, Moffitt celebrated 25 years of oncology nursing,” said Jane Fusilero, Vice President and Chief Nursing Officer of Moffitt. “We are honored to be recognized by the society.”
Thomas Look, MD and Kimberly Stegmaier, MD, both of Dana-Farber Cancer Institute, and Adolfo Ferrando, MD, PhD, of Columbia University Medical Center have each been named recipients of a one-year, $100,000 Bridge Grant from Alex's Lemonade Stand Foundation.
Look's research examines reasons for first-line therapy failure for children with T-cell acute lymphoblastic leukemia and aims to develop improved targeted therapies for this subset of high-risk patients. Stegmaier's research focuses on developing new therapies for patients with Ewing sarcoma of the bones or soft tissue surrounding bone. And Ferrando's research analyzes the role of the NOTCH1 gene in the development of T-cell ALL in order to improve targeted therapy for children with the disease.
These awards are the inaugural three Bridge Grants, which are designed to allow promising projects denied of NIH grants to continue while the researchers reapply for funding.
Send information and photos for this column to OT@LWWNY.com© 2012 Lippincott Williams & Wilkins, Inc.
More on ONCOLOGY-TIMES.com...